|
1
|
Agnes F, Shamoon B, Dina C, Rosnet O,
Birnbaum D and Galibert F: Genomic structure of the downstream part
of the human FLT3 gene: Exon/intron structure conservation among
genes encoding receptor tyrosine kinases (RTK) of subclass III.
Gene. 145:283–288. 1994.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Thiede C, Steudel C, Mohr B, Schaich M,
Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M,
Neubauer A, et al: Analysis of FLT3-activating mutations in 979
patients with acute myelogenous leukemia: Association with FAB
subtypes and identification of subgroups with poor prognosis.
Blood. 99:4326–4335. 2002.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Meshinchi S, Stirewalt DL, Alonzo TA,
Zhang Q, Sweetser DA, Woods WG, Bernstein ID, Arceci RJ and Radich
JP: Activating mutations of RTK/ras signal transduction pathway in
pediatric acute myeloid leukemia. Blood. 102:1474–1479.
2003.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kiyoi H, Yanada M and Ozekia K: Clinical
significance of FLT3 in leukemia. Int J Hematol. 82:85–92.
2005.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sheikhha MH, Awan A, Tobal K and Liu Yin
JA: Prognostic significance of FLT3 ITD and D835 mutations in AML
patients. Hematol J. 4:41–46. 2003.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Meshinchi S, Stirewalt DL, Alonzo TA,
Boggon TJ, Gerbing RB, Rocnik JL, Lange BJ, Gilliland DG and Radich
JP: Structural and numerical variation of FLT3/ITD in pediatric
AML. Blood. 111:4930–4933. 2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Santos FP, Jones D, Qiao W, Cortes JE,
Ravandi F, Estey EE, Verma D, Kantarjian H and Borthakur G:
Prognostic value of FLT3 mutations among different cytogenetic
subgroups in acute myeloid leukemia. Cancer. 117:2145–2155.
2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gale RE, Green C, Allen C, Mead AJ,
Burnett AK, Hills RK and Linch DC: Medical Research Council Adult
Leukaemia Working Party. The impact of FLT3 internal tandem
duplication mutant level, number, size, and interaction with NPM1
mutations in a large cohort of young adult patients with acute
myeloid leukemia. Blood. 111:2776–2784. 2008.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Pemmaraju N, Kantarjian H, Ravandi F and
Cortes J: FLT3 inhibitors in the treatment of acute myeloid
leukemia: The start of an era? Cancer. 117:3293–3304.
2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Knapper S: The clinical development of
FLT3 inhibitors in acute myeloid leukemia. Expert Opin Investig
Drugs. 20:1377–1395. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kindler T, Lipka D and Fischer T: FLT3 as
a therapeutic target in AML: Still challenging after all these
years. Blood. 116:5089–5102. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Cortes JE, Khaled S, Martinelli G, Perl
AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA,
et al: Quizartinib versus salvage chemotherapy in relapsed or
refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A
multicentre, randomised, controlled, open-label, phase 3 trial.
Lancet Oncol. 20:984–997. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pratz K and Levis M: Incorporating FLT3
inhibitors into acute myeloid leukemia treatment regimens. Leuk
Lymphoma. 49:852–863. 2008.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Fischer T, Stone RM, Deangelo DJ, Galinsky
I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, et
al: Phase IIB trial of oral Midostaurin (PKC412), the FMS-like
tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase
inhibitor, in patients with acute myeloid leukemia and high-risk
myelodysplastic syndrome with either wild-type or mutated FLT3. J
Clin Oncol. 28:4339–4345. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lotan R: Suppression of squamous cell
carcinoma growth and differentiation by retinoids. Cancer Res. 54
(7 Suppl)(1987S-1990S)1994.PubMed/NCBI
|
|
16
|
Amos B and Lotan R: Retinoid-sensitive
cells and cell lines. Methods Enzymol. 190:217–225. 1990.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Conley BA, Egorin MJ, Sridhara R, Finley
R, Hemady R, Wu S, Tait NS and Van-Echo DA: Phase I clinical trial
of all-trans-retinoic acid with correlation of its pharmacokinetics
and pharmacodynamics. Cancer Chemother Pharmacol. 39:291–299.
1997.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Karmakar S, Banik NL and Ray SK:
Combination of all-trans retinoic acid and paclitaxel-induced
differentiation and apoptosis in human glioblastoma U87MG
xenografts in nude mice. Cancer. 112:596–607. 2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chi HT, Ly BT, Vu HA, Sato Y, Dung PC and
Xinh PT: Synergistic effect of alltrans retinoic acid in
combination with protein kinase C 412 in FMS-like tyrosine kinase
3-mutated acute myeloid leukemia cells. Mol Med Rep. 11:3969–3975.
2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shanafelt TD, Call TG, Zent CS, LaPlant B,
Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, et al:
Phase I trial of daily oral Polyphenon E in patients with
asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin
Oncol. 27:3808–3814. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Liu Q, Qian Y, Chen F, Chen X, Chen Z and
Zheng M: EGCG attenuates pro-inflammatory cytokines and chemokines
production in LPS-stimulated L02 hepatocyte. Acta Biochim Biophys
Sin (Shanghai). 46:31–39. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chuu CP, Chen RY, Kokontis JM, Hiipakka RA
and Liao S: Suppression of androgen receptor signaling and prostate
specific antigen expression by (-)-epigallocatechin-3-gallate in
different progression stages of LNCaP prostate cancer cells. Cancer
Lett. 275:86–92. 2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sanchez-Tena S, Vizan P, Dudeja PK,
Centelles JJ and Cascante M: Green tea phenolics inhibit
butyrate-induced differentiation of colon cancer cells by
interacting with monocarboxylate transporter 1. Biochim Biophys
Acta. 1832:2264–2270. 2013. View Article : Google Scholar
|
|
24
|
Singh T and Katiyar SK: Green tea
polyphenol, (-)-epigallocatechin-3-gallate, induces toxicity in
human skin cancer cells by targeting β-catenin signaling. Toxicol
Appl Pharmacol. 273:418–424. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Belguise K, Guo S and Sonenshein GE:
Activation of FOXO3a by the green tea polyphenol
epigallocatechin-3-gallate induces estrogen receptor alpha
expression reversing invasive phenotype of breast cancer cells.
Cancer Res. 67:5763–5770. 2007.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ly BT, Chi HT, Yamagishi M, Kano Y, Hara
Y, Nakano K, Sato Y and Watanabe T: Inhibition of FLT3 expression
by green tea catechins in FLT3 mutated-AML cells. PLoS One.
8(e66378)2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Timm M, Saaby L, Moesby L and Hansen EW:
Considerations regarding use of solvents in in vitro cell based
assays. Cytotechnology. 65:887–894. 2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Thanh Chi H, Anh Vu H, Iwasaki R, Thao le
B, Hara Y, Taguchi T, Watanabe T and Sato Y: Green tea
(-)-Epigalocatechin-3-gallate inhibits KIT activity and causes
caspase-dependent cell death in gastrointestinal stromal tumor
including imatinib-resistant cells. Cancer Bio Ther. 8:1934–1939.
2009.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Steel GG and Peckham MJ: Exploitable
mechanisms in combined radiotherapy-chemotherapy: The concept of
additivity. Int J radiat Oncol. 5(85)1979.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kano Y, Ohnuma T, Okano T and Holland JF:
Effects of vincristine in combination with methotrexate and other
antitumor agents in human acute lymphoblastic leukemia cells in
culture. Cancer Res. 48:351–356. 1988.PubMed/NCBI
|
|
31
|
Kano Y, Akutsu M, Tsunoda S, Mori K,
Suzuki K and Adachi KI: In vitro schedule-dependent interaction
between paclitaxel and SN-38 (the active metabolite of irinotecan)
in human carcinoma cell lines. Cancer Chemother Pharmacol.
42:91–98. 1998.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Team RC: R: A language and environment for
statistical computing. Journal. 2018.
|
|
33
|
Kini AR, Peterson LA, Tallman MS and
Lingen MW: Angiogenesis in acute promyelocytic leukemia: Induction
by vascular endothelial growth factor and inhibition by all-trans
retinoic acid. Blood. 97:3919–3924. 2001.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Degos L, Dombret H, Chomienne C, Daniel
MT, Micléa JM, Chastang C, Castaigne S and Fenaux P:
All-trans-retinoic acid as a differentiating agent in the treatment
of acute promyelocytic leukemia. Blood. 85:2643–2653.
1995.PubMed/NCBI
|
|
35
|
Rubnitz JE, Gibson B and Smith FO: Acute
myeloid leukemia. Hematol Oncol Clin North Am. 24:35–63.
2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Nagai S, Takenaka K, Sonobe M, Wada H and
Tanaka F: Schedule-dependent synergistic effect of pemetrexed
combined with gemcitabine against malignant pleural mesothelioma
and non-small cell lung cancer cell lines. Chemotherapy.
54:166–175. 2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Torchilin V: Antibody-modified liposomes
for cancer chemotherapy. Expert Opin Drug Deliv. 5:1003–1025.
2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lee JH, Kishikawa M, Kumazoe M, Yamada K
and Tachibana H: Vitamin A enhances antitumor effect of a green tea
polyphenol on melanoma by upregulating the polyphenol sensing
molecule 67-kDa Laminin Receptor. PLoS One.
5(e11051)2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Britschgi A, Simon HU, Tobler A, Fey M and
Tschan M: Epigallocatechin-3-gallate induces cell death in acute
myeloid leukaemia cells and supports all-trans retinoic
acid-induced neutrophil differentiation via death-associated
protein kinase 2. Br J Haematol. 149:55–64. 2010.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Yao S, Zhong L, Chen M, Zhao Y, Li L, Liu
L, Xu T, Xiao C, Gan L, Shan Z and Liu B:
Epigallocatechin-3-gallate promotes all-trans retinoic acid-induced
maturation of acute promyelocytic leukemia cells via PTEN. Int J
Oncol. 51:899–906. 2017.PubMed/NCBI View Article : Google Scholar
|
